Health News Roundup: Humana's Medicare Decline, J&J's Major Investment, and More

This summary covers recent developments in health news, from Humana's slumping Medicare plan enrollments impacting future revenue, J&J's $2 billion investment in a new North Carolina facility, and CVS exploring a break-up. Other highlights include Pfizer reducing its Haleon stake and WHO's new RSV prevention recommendations.

Humana shares nosedived as 2025 enrollments for top-rated Medicare plans took a hit, significantly affecting future revenue and bonuses. The company reported a steep drop, with only 25% of members enrolled in highly-rated plans, compared to 94% previously.

In a massive boost to its production capabilities, Johnson & Johnson announced a $2 billion investment in a new North Carolina facility. This move aims to enhance the production of biologic medicines for treating cancer and other diseases.

CVS Health is mulling a potential split of its retail and insurance units, according to insiders. This comes as the company faces mounting investor pressure and explores various strategic options to improve its performance.

(With inputs from agencies.)